DTMC
Studies associated with:
Division of Therapeutics and Medical Consequences
| Division | Study Number | Title | Investigator(s) | Release Date |
|---|---|---|---|---|
| DTMC | NIDA-CSP-1033 | Phase 2, Multi-Center Trial of Lorcaserin in the Treatment of Cocaine Use Disorder | Shwe Gyaw, M.D. | |
| DTMC | NIDA-CPU-0011 | Ph1 Marinol Interaction Study - Part 1 | Louis Cantilena, Jr., M.D, Ph.D. | |
| DTMC | NIDA-CPU-0010 | Assessment of Potential Interactions Between Intravenous Cocaine and Atomoxetine | Louis Cantilena, Jr., M.D, Ph.D. | |
| DTMC | NIDA-CTO-0011 | Double-Blind, Placebo-Controlled, Dose Response Trial Of Ondansetron For The Treatment Of Methamphetamine Dependence | Bankole Johnson, DSc., M.D., Ph.D. | |
| DTMC | NIDA-CTO-0012 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Tiagabine For The Treatment Of Cocaine Dependence | Eugene Somoza, M.D. | |
| DTMC | NIDA-MDS-0002 | Assessment of Interactions Between Methamphetamine and Aripiprazole | Thomas F. Newton, M.D. | |
| DTMC | NIDA-CTO-0010 | Assessment of Potential Interactions Between Methamphetamine and Bupropion | Thomas F. Newton, M.D. | |
| DTMC | NIDA-CTO-0008 | Phase 2, Double-Blind Placebo-Controlled Trial Of Bupropion for the Treatment of Methamphetamine Dependence | Richard Rawson, Ph.D. | |
| DTMC | NIDA-CSP-1022 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Selegiline Transdermal System (STS) As An Aid For Smoking Cessation | Elbert D. Glover, PhD, FASHA, FAAHB, FRIPH | |
| DTMC | NIDA-CSP-1021 | Double-Blind, Placebo-Controlled Multi-Center Trial Of Baclofen For The Treatment Of Cocaine Dependence | Liza Gorgon, M.A. | |
| DTMC | NIDA-CSP-1019 | Double-Blind, Placebo-Controlled Trial Of Selegiline Transdermal System For The Treatment Of Cocaine Dependence | Ahmed Elkashef, M.D., Paul J. Fudala, Ph.D. | |
| DTMC | NIDA-MDS-0003 | Phase I, Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Cocaine And Ethanol And Oral Disulfiram | John D. Roache, Ph.D. | |
| DTMC | NIDA-CPU-0008 | Double-Blind, Placebo-Controlled Assessment of Interactions Between Intravenous Methamphetamine and Modafinil | Reese Jones, M.D. | |
| DTMC | NIDA-CTO-0007 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Cabergoline For The Treatment Of Cocaine Dependence | Steven Shoptaw, Ph.D., Thomas F. Newton, M.D. | |
| DTMC | NIDA-CSP-1020 | A Phase III Placebo-Controlled, Double-Blind Multi-Site Trial of Lofexidine for Opiate Withdrawal | Ann Montgomery, R.N. | |
| DTMC | NIDA-CPU-0005 | Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. | Louis Cantilena, Jr., M.D, Ph.D. | |
| DTMC | NIDA-CPU-0004 | Study of Interactions Between GBR 12909 and Cocaine | Kathryn Cunningham, Ph.D., John Grabowski, Ph.D. | |
| DTMC | NIDA-CPU-0006 | A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine | Reese Jones, M.D. | |
| DTMC | NIDA-CPU-0003 | Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681 | Louis Cantilena, Jr., M.D, Ph.D. | |
| DTMC | NIDA-CPU-0002 | Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers | Louis Cantilena, Jr., M.D, Ph.D. | |
| DTMC | NIDA-CTO-0006 | Cocaine-Metyrapone Interaction Study | Bonita Singal, M.D., T. John Winhusen, Ph.D. | |
| DTMC | NIDA-CTO-0005 | Double-Blind, Placebo-Controlled Trial Of Ondansetron For The Treatment Of Cocaine Dependence | John D. Roache, Ph.D. | |
| DTMC | NIDA-CTO-0004 | Assessment Of Potential Interactions Between Intravenous Methamphetamine And Oral Selegiline | Thomas F. Newton, M.D. | |
| DTMC | NIDA-CTO-0003 | Assessment Of Potential Interactions Between Intravenous Cocaine And Tolcapone | Thomas F. Newton, M.D. | |
| DTMC | NIDA-CTO-0002 | Safety Evaluation Of Cocaine Treatment Medication, Modafinil: Interactions With Intravenous Cocaine | Robert J. Malcolm, M.D., C. Lindsay DeVane, Pharm.D. | |
| DTMC | NIDA-MDS-0007 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Bupropion For Methamphetamine Dependence | Ann Anderson, M.D. | |
| DTMC | NIDA-MDS-0004 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Modafinil For The Treatment Of Cocaine Dependence | Domenic Ciraulo, M.D. | |
| DTMC | NIDA-CTO-0001 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Reserpine For The Treatment Of Cocaine Dependence | Eugene Somoza, M.D. | |
| DTMC | NIDA-CSP-1026 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Modafinil For Methamphetamine Dependence | Ahmed Elkashef, M.D. | |
| DTMC | NIDA-CSP-1025 | Phase 2, Double-Blind, Placebo-Controlled Trial Of Topiramate For The Treatment Of Methamphetamine Dependence | Bankole Johnson, DSc., M.D., Ph.D. | |
| DTMC | NIDA-CSP-1018 | A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence | Walter Ling, M.D., Paul J. Fudala, Ph.D., Paul Casadonte, M.D. | |
| DTMC | NIDA-CSP-1008B | A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence | Peter Bridge, M.D. | |
| DTMC | NIDA-CSP-1008A | A Multicenter Efficacy/Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence | Peter Bridge, M.D., Paul J. Fudala, Ph.D. | |
| DTMC | NIDA-CSP-999 | A Multicenter Clinical Trial of Buprenorphine in Treatment of Opiate Dependence | Walter Ling, M.D., Donald R. Wesson, M.D., C. James Klett, Ph.D. | |
| DTMC | NIDA-CPU-0016 | Double-Blind, Placebo-Controlled Assessment Of Potential Interactions Between Intravenous Methamphetamine And Osmotic-Release Methylphenidate (Oros-Mph) | Eugene Somoza, M.D. |